The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial
Open accessAbstract
BACKGROUND: Limited data suggest a benefit of population-based screening for cardiovascular disease with respect to the risk of death. METHODS: We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality. Only the control group was unaware of the trial-group assignments. Screening included noncontrast electrocardiography-gated computed tomography to determine the coronary-artery calcium score and to detect aneurysms and atrial fibrillation, ankle-brachial blood-pressure measurements to detect peripheral artery disease and hypertension, and a blood sample to detect diabetes mellitus and hypercholesterolemia. The primary outcome was death from any cause. RESULTS: A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died (hazard ratio, 0.95; 95% confidence interval [CI], 0.90 to 1.00; P = 0.06). The hazard ratio for stroke in the invited group, as compared with the control group, was 0.93 (95% CI, 0.86 to 0.99); for myocardial infarction, 0.91 (95% CI, 0.81 to 1.03); for aortic dissection, 0.95 (95% CI, 0.61 to 1.49); and for aortic rupture, 0.81 (95% CI, 0.49 to 1.35). There were no significant between-group differences in safety outcomes. CONCLUSIONS: After more than 5 years, the invitation to undergo comprehensive cardiovascular screening did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age. (Funded by the Southern Region of Denmark and others; DANCAVAS ISRCTN Registry number, ISRCTN12157806.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Earlier onset of metabolic risk factors is associated with increased risk for CVD and mortality, motivating the timely identification and treatment of risk factors.47–49”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the ICER varied widely based on the cost of therapy and the comparator chosen.49”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Both SGLT2i and GLP-1–based therapy improve kidney outcomes,49–51 with GLP-1–based therapy additionally promoting significant weight reduction and glycemic control (especially semaglutide and tirzepatide)19–25 and reducing liver fibrosis in MASH”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Finally, sedentary behavior is an independent predictor of MASLD and is associated with a high risk for MASLD progression.49,50”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“Moreover, in a recently published RCT involving men aged 65-74 years, routine CVD screening did not significantly reduce the incidence of death from any cause after a median follow-up of 5.6 years, also in a pre-specified diabetes sub-group.296”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [296]
In the citing paper
“Routine screening for coronary artery disease in asymptomatic individuals has not been beneficial and should not be considered in TS.485”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [485]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Generation of a Danish TTO value set for EQ-5D health states
Wittrup-Jensen, K. U., Lauridsen, J. T., Gudex, C. M., & Pedersen, K. M. (2009) · Scandinavian Journal of Public Health · doi:10.1177/1403494809105287 · Cited by 262
Lindholt, J. S., & Søgaard, R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32250-x · Cited by 234
Self-citationChallenges and Opportunities for Cardiovascular Disease Prevention
Franco, M., Cooper, R., Bilal, U., & Fuster, V. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.08.015 · Cited by 142
Diederichsen, A. C. P., Rasmussen, L. M., Søgaard, R., Lambrechtsen, J., Steffensen, F. H., Frost, L., Egstrup, K., Urbonavičienė, G., Busk, M., Olsen, M. H., et al. (2015) · Trials · doi:10.1186/s13063-015-1082-6 · Cited by 82
Self-citationSøgaard, R., Laustsen, J., & Lindholt, J. S. (2012) · BMJ · doi:10.1136/bmj.e4276 · Cited by 64
Self-citationLindholt, J. S., Rasmussen, L. M., Søgaard, R., Lambrechtsen, J., Steffensen, F. H., Frost, L., Egstrup, K., Urbonavičienė, G., Busk, M., Olsen, M. H., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11135 · Cited by 55
Self-citationKvist, T. V., Lindholt, J. S., Rasmussen, L. M., Søgaard, R., Lambrechtsen, J., Steffensen, F. H., Frost, L., Olsen, M. H., Mickley, H., Hallas, J., et al. (2016) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2016.10.010 · Cited by 39
Self-citationUmbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease
Ambler, G. K., Waldron, C.-A., Contractor, U. B., Hinchliffe, R. J., & Twine, C. P. (2020) · Journal of British Surgery · doi:10.1002/bjs.11384 · Cited by 35
Søgaard, R., Diederichsen, A. C. P., Rasmussen, L. M., Lambrechtsen, J., Steffensen, F. H., Frost, L., Egstrup, K., Urbonavičienė, G., Busk, M., & Lindholt, J. S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac488 · Cited by 26
Self-citationWhy and when to screen for cardiovascular disease in healthy individuals
Lindholt, J. S., & Søgaard, R. (2021) · Heart · doi:10.1136/heartjnl-2019-316266 · Cited by 20
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixidó‐Turà, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., Backer, J. F. A. D., Déglise, S., Corte, A. D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 1,313
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Metadata
- Authors
- Lindholt, J. S., Søgaard, R., Rasmussen, L. M., Mejldal, A., Lambrechtsen, J., Steffensen, F. H., Frost, L., Egstrup, K., Urbonaviciene, G., Busk, M., & Diederichsen, A. C. P.
- Affiliations
- University of Southern Denmark (DK)
- From the Departments of Cardiac, Thoracic, and Vascular Surgery (J.S.L., R.S.), Clinical Biochemistry and Pharmacology (L.M.R.), and Cardiology (A.C.P.D.), Elite Research Center for Individualized Medicine in Arterial Diseases, and the Open Patient Data Explorative Network (A.M.), Odense University Hospital, Clinical Institute, University of Southern Denmark (R.S.), Odense, the Department of Cardiology, Odense University Hospital, Svendborg (J.L., K.E.), the Department of Cardiology, Lillebaelt Hospital, Vejle (F.H.S., M.B.), and the Department of Cardiology, Diagnostic Center, Regional Hospital Silkeborg, Silkeborg (L.F., G.U.) — all in Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-10-13
- Volume
- 387
- Issue
- 15
- Pages
- 1385-1394
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293872316
- Semantic Scholar
- e45554186343dbbd4336d0fe7a98a8b8783cffbe
- Cited by
- 182
- References
- 13
- Citations by year
- 2026: 34 · 2025: 53 · 2024: 39 · 2023: 42 · 2022: 12
- FWCI
- 32.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Hjerteforeningen
- Danish Independent Research Councils
- Helsefonden
- Odense Universitetshospital
- Region of Southern Denmark
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Health Sciences › Medicine › Epidemiology › Healthcare Systems and Public Health
- Keywords
- cardiovascular screening, coronary artery calcium score, aortic aneurysm, atrial fibrillation, peripheral arterial disease, hypertension, diabetes mellitus, hypercholesterolemia, all-cause mortality, stroke, myocardial infarction, aortic dissection, aortic rupture
- MeSH terms
- Aged, Calcium, Cardiovascular Diseases, Denmark, Humans, Male, Mass Screening, Incidence, Cardiac-Gated Imaging Techniques, Peripheral Arterial Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
